Siti Aisyah Mualif

Dr. Siti Aisyah Mualif

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Open access
YTYoong Mond Teh
Yoong Mond Teh
SMSiti Aisyah Mualif
Siti Aisyah Mualif
Soo Kun LimSoo Kun Lim
Soo Kun Lim
As part of the glomerular filtration membrane, podocyte is terminally differentiated, structurally unique, and highly specialized in maintaining kidney function. Proteinuria caused by podocyte injury (foot process effacement) is the clinical symptom of various kidney diseases (CKD), including nephrotic syndrome. Podocyte autophagy has become a powerful therapeutic strategy target in ameliorating podocyte injury. Autophagy is known to be associated significantly with sirtuin-1, proteinuria, and podocyte injury. Various key findings in podocyte autophagy were reported in the past ten years, such as the role of endoplasmic reticulum (ER) stress in podocyte autophagy impairment, podocyte autophagy-related gene, essential roles of the signaling pathways: Mammalian Target of Rapamycin (mTOR)/ Phosphoinositide 3-kinase (PI3k)/ serine/threonine kinase 1 (Akt) in podocyte autophagy. These significant factors caused podocyte injury associated with autophagy impairment. Sirtuin-1 was reported to have a vital key role in mTOR signaling, 5'AMP-activated protein kinase (AMPK) regulation, autophagy activation, and various critical pathways associated with podocyte's function and health; it has potential value to podocyte injury pathogenesis investigation. From these findings, podocyte autophagy has become an attractive therapeutic strategy to ameliorate podocyte injury, and this review will provide an in-depth review on therapeutic targets he podocyte autophagy.

Verified
Journal Article
Open access
PDF file
YTYoong Mond Teh
Yoong Mond Teh
SMSiti Aisyah Mualif
Siti Aisyah Mualif
NNNur Izzati Mohd Noh
Nur Izzati Mohd Noh
Soo Kun LimSoo Kun Lim
Soo Kun Lim
Chronic kidney disease (CKD) is characterized by irreversible progressive worsening of kidney function leading to kidney failure. CKD is viewed as a clinical model of premature aging and to date, there is no treatment to reverse kidney damage. The well-established treatment for CKD aims to control factors that may aggravate kidney progression and to provide kidney protection effects to delay the progression of kidney disease. As an alternative, Traditional Chinese Medicine (TCM) has been shown to have fewer adverse effects for CKD patients. However, there is a lack of clinical and molecular studies investigating the mechanisms by which natural products used in TCM can improve CKD. In recent years, autophagy and cellular senescence have been identified as key contributors to aging and age-related diseases. Exploring the potential of natural products in TCM to target these processes in CKD patients could slow disease progression. A better understanding of the characteristics of these natural products and their effects on autophagy and cellular senescence through clinical studies, coupled with the use of these products as complementary therapy alongside mainstream treatment, may maximize therapeutic benefits and minimize adverse effects for CKD patients. While promising, there is currently a lack of thorough research on the potential synergistic effects of these natural products. This review examines the use of natural products in TCM as an alternative treatment for CKD and discusses their active ingredients in terms of renoprotection, autophagy, and cellular senescence.

6 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YTYoong Mond Teh
Yoong Mond Teh
Soo Kun LimSoo Kun Lim
Soo Kun Lim
Norhana JusohNorhana Jusoh
Norhana Jusoh
KOKahar Osman
Kahar Osman
SMSiti Aisyah Mualif
Siti Aisyah Mualif
Minimal change disease (MCD) is the most common cause of idiopathic nephrotic syndrome in children, and it is well known for its multifactorial causes which are the manifestation of the disease. Proteinuria is an early consequence of podocyte injury and a typical sign of kidney disease. Steroid‐sensitive patients react well with glucocorticoids, but there is a high chance of multiple relapses. CD80, also known as B7‐1, is generally expressed on antigen‐presenting cells (APCs) in steroid‐sensitive MCD patients. Various glomerular disease models associated with proteinuria demonstrated that the detection of CD80 with the increase of urinary CD80 was strongly associated closely with frequent‐relapse MCD patients. The role of CD80 in MCD became controversial because one contradicts finding. This review covers the treatment alternatives for MCD with the insight of CD80 as a potential therapeutic target. The promising effectiveness of CD20 (rituximab) antibody and CD80 inhibitor (abatacept) encourages further investigation of CD80 as a therapeutic target in frequent‐relapse MCD patients. Therapeutic‐based antibody towards CD80 (galiximab) had never been investigated in MCD or any kidney‐related disease; hence, the role of CD80 is still undetermined. A new therapeutic approach towards MCD is essential to provide broader effective treatment options besides the general immunosuppressive agents with gruesome adverse effects.

13 February 2025 in Frontiers in Bioinformatics
Verified
Journal Article
Open access
PDF file
TSTasshitra Subramaniam
Tasshitra Subramaniam
SMSiti Aisyah Mualif
Siti Aisyah Mualif
WCWeng Howe Chan
Weng Howe Chan
KHKhairul Bariyyah Abd Halim
Khairul Bariyyah Abd Halim
Antibodies are naturally produced safeguarding proteins that the immune system generates to fight against invasive invaders. For centuries, they have been produced artificially and utilized to eradicate various infectious diseases. Given the ongoing threat posed by COVID-19 pandemics worldwide, antibodies have become one of the most promising treatments to prevent infection and save millions of lives. Currently, in silico techniques provide an innovative approach for developing antibodies, which significantly impacts the formulation of antibodies. These techniques develop antibodies with great specificity and potency against diseases such as SARS-CoV-2 by using computational tools and algorithms. Conventional methods for designing and developing antibodies are frequently costly and time-consuming. However, in silico approach offers a contemporary, effective, and economical paradigm for creating next-generation antibodies, especially in accordance with recent developments in bioinformatics. By utilizing multiple antibody databases and high-throughput approaches, a unique antibody construct can be designed in silico, facilitating accurate, reliable, and secure antibody development for human use. Compared to their traditionally developed equivalents, a large number of in silico-designed antibodies have advanced swiftly to clinical trials and became accessible sooner. This article helps researchers develop SARS-CoV-2 antibodies more quickly and affordably by giving them access to current information on computational approaches for antibody creation.

10 September 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
HDHuaping Ding
Huaping Ding
HCHuanghe Cheng
Huanghe Cheng
JWJiaxian Wu
Jiaxian Wu
FZFan Zhang
Fan Zhang
CCCan Cao
Can Cao
MSMohd Helmi Sani
Mohd Helmi Sani
Monoclonal antibody drugs have grown into a drug category with a market size of over $100 billion since the first product was launched on the market, which naturally creates a large demand for production. At the same time, the $100 billion market is distributed among more than 200 listed drugs, which indicates that the production demand for monoclonal antibody drugs is diverse. To meet this demand, major suppliers offer single-use bioreactors of all sizes. These single-use bioreactors with different specifications, especially the inconsistency of aeration pore sizes, pose great challenges for technology transfer and scale-up production, and the conventional scale-up strategies of constant Power input/volume ratio (P/V) and constant vessel volume per minute (vvm) can no longer meet the needs. This study simplified the selection of technical parameters in bioreactors based on the differences in aeration pore size. Innovatively combined the aeration pore sizes with initial aeration vvm, and comprehensively investigated the relationship between P/V, vvm and aeration pore size by designing experiments (DoE) using the orthogonal test method. The results showed a quantitative relationship between the aeration pore size and the initial aeration vvm in the P/V range of 20 ± 5 W/m3. The appropriate initial aeration was between 0.01 and 0.005 m3/min for aeration pore size ranging from 1 to 0.3 mm, which was the optimal incubation condition in the bioreactors. The choice of initial ventilation was most related to the final expression. Follow-up studies validated these findings in a 15 L glass bioreactor and a 500 L single-use bioreactor, and the results were consistent with expectations.

30 June 2024 in Journal of Medical Device Technology
Verified
Journal Article
Open access
PDF file
OAObadah Alali
Obadah Alali
OMOhoud Samir Basir Mohamed
Ohoud Samir Basir Mohamed
SKSin Bie Kie
Sin Bie Kie
OXOng Ke Xin
Ong Ke Xin
YLYvonne Wong Liang Liang
Yvonne Wong Liang Liang
SMSiti Aisyah Mualif
Siti Aisyah Mualif
The SoleMate smart insole system, introduced in this study, addresses the growing prevalence of foot disorders and their associated complications. Foot disorders affect a substantial portion of the population, leading to foot pain and gait abnormalities. This research presents a low-cost, innovative solution that combines force-sensitive resistors (FSR), vibration motors, and a gyroscope sensor integrated with an ESP32 microcontroller. This system offers continuous monitoring of foot alignment and plantar pressure, along with the ability to provide alerts for abnormal foot alignment. By utilizing the Internet of Things (IoT) technology through the Blynk app, users can remotely monitor and control the device, enhancing its usability and potential for early detection and intervention in foot-related issues. While the SoleMate system shows promise, there is room for improvement, including reducing the system's size, adding sensors to enhance data collection, and improving the user interface. With its potential to improve foot health and overall well-being, the SoleMate system holds promise for healthcare professionals and individuals seeking effective foot-related problem management and prevention.